Brickell Biotech CFO resigns to fully commit to Edgewise Therapeutics

BOULDER — R. Michael Carruthers, the chief financial officer and head accountant for Brickell Biotech inc. (Nasdaq: BII), is resigning from the company to fully commit to fellow Boulder-based biopharmaceutical firm Edgewise Therapeutics Inc.

In a filing to the U.S. Securities and Exchange Commission Tuesday morning, the Boulder-based Brickell said Carruthers would resign effective at the end of the month. 

Carruthers, a veteran finance officer of multiple Boulder-area clinical companies, was acting as an independent CFO consultant before joining Edgewise Therapeutics in September as its full-time CFO.

SPONSORED CONTENT

Federal District Court Rules Corporate Transparency Act Unconstitutional . . . But Most Small Businesses Must Still Comply

Lyons Gaddis Real Estate and Business Attorney Cameron Grant shares important details of the Corporate Transparency Act (CTA).

Brickell said it will hire Albert Marchio II as a part-time CFO in December, and promote Jose Breton as its chief accounting officer. Breton joined the company after it acquired Vical Inc. in a reverse initial public offering last year.

Brickell’s Sofpironium Bromide treatment for excessive underarm sweating has recently been approved for sale in Japan, and is recruiting patients for a Phase III trial in the U.S. That trial is currently expected to end next July.